Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

~22 mi. (Alkmaar, Netherlands, +226 more cities)

Noordwest Ziekenhuisgroep NWZ ( Site 0468)

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type

Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

~22 mi. (Alkmaar, Netherlands, +54 more cities)

Medisch Centrum Alkmaar

Colorectal Carcinoma

bevacizumab, +6 more drugs

chemotherapy, +1 more type

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

~29 mi. (De Haal, Netherlands, +192 more cities)

Haga Ziekenhuis locatie Leyweg

ER Positive, +1 more biomarker

Breast Carcinoma

abemaciclib, +1 more drug

hormone therapy, +1 more type

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

~29 mi. (De Haal, Netherlands, +206 more cities)

Hagaziekenhuis Van Den Haag - Leyweg

Non-Squamous Non-Small Cell Lung Carcinoma

nivolumab, +1 more drug

immunotherapy, +1 more type

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

~29 mi. (De Haal, Netherlands, +43 more cities)

Hagaziekenhuis

Prostate Carcinoma

HC-1119

hormone therapy

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

~37 mi. (Amsterdam, Netherlands, +89 more cities)

Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL) ( Site 1351)

ER Positive, +2 more biomarkers

Breast Carcinoma

capecitabine, +4 more drugs

chemotherapy, +1 more type

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

~37 mi. (Amsterdam, Netherlands, +140 more cities)

AMC ( Site 0438)

Hepatocellular Carcinoma

lenvatinib, +2 more drugs

chemotherapy, +2 more types

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

~37 mi. (Amsterdam, Netherlands, +127 more cities)

Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)

BRAF V600E

Colorectal Carcinoma

cetuximab, +3 more drugs

chemotherapy, +1 more type

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

~37 mi. (Amsterdam, Netherlands, +356 more cities)

Amsterdam UMC - VU Medisch Centrum

HER2 Positive

Invasive Breast Carcinoma

fam-trastuzumab deruxtecan

targeted therapy

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

~37 mi. (Amsterdam, Netherlands, +93 more cities)

Antoni van Leeuwenhoek Ziekenhuis ( Site 1901)

Clear Cell Renal Cell Carcinoma

belzutifan, +1 more drug

targeted therapy

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

~37 mi. (Amsterdam, Netherlands, +92 more cities)

Netherlands Cancer Institute (NKI) ( Site 0183)

Bladder Urothelial Carcinoma

chemotherapy, +2 more drugs

chemotherapy, +2 more types

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

~37 mi. (Amsterdam, Netherlands, +209 more cities)

Netherlands Cancer Institute

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

targeted therapy